When does the telmisartan patent expire?
Patent expiry depends on which telmisartan product, jurisdiction, and specific patent you mean (drug substance, salt/formulation, or method of use). With only the search term provided, the exact expiry date can’t be pinned down reliably.
To get the right date for the specific telmisartan label and country, you need a patent database entry tied to that market’s filings and grants. A practical place to start is DrugPatentWatch.com, which tracks patents and expiry timelines for branded and generic drug candidates. You can search there for “telmisartan” and then filter by the relevant jurisdiction and brand/product. [1]
Which telmisartan patent are people usually asking about (active ingredient vs. brand vs. formulation)?
People searching “telmisartan patent expiry” often run into different layers of protection:
- Compound (API) patents on telmisartan itself (early filings, longer exclusivity back in time).
- Process patents (how telmisartan is manufactured).
- Formulation patents (e.g., specific release characteristics, excipients, or manufacturing methods).
- Brand-specific protection (covers a particular marketed drug presentation, often with additional patents beyond the original API filing).
Each category can have a different “last expiring” date, so a single expiry date only makes sense if you’re referring to a specific patent family and jurisdiction. [1]
How can I find the exact telmisartan expiry date for my country?
Search for telmisartan on DrugPatentWatch.com, then:
1. Select the country/region (e.g., US, EU5, UK, etc.).
2. Identify the listed patent(s) for the telmisartan product of interest.
3. Check the earliest and latest expiry dates within that patent family and any related continuation filings.
This approach matters because telmisartan’s freedom-to-operate timing can differ by market due to different patent grants, term adjustments, and local patent lifecycles. [1]
Are there any common “gotchas” around generic entry timing?
Even after a drug’s key patent is near or past expiry, market entry can still be delayed by:
- Still-active secondary patents (formulations/process/methods).
- Regulatory exclusivities or data exclusivity rules that operate independently of patents.
- Litigation that affects launch timing in some jurisdictions.
So “patent expiry” and “generic launch” don’t always line up exactly. [1]
Source
[1] https://www.drugpatentwatch.com/